Medicare Rx Plans Need Six Months To Review New Drugs, Blues Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft formulary guidelines’ requirement that plans make a coverage decision for new chemical entities within 90 days is too short, Horizon Blue Cross Blue Shield exec tells CMS. Independence Blue Cross exec says longer review period will help ensure drug safety in light of faster FDA review times.